Madrigal CCO Remy Sukhija departs; receives 12-month severance, bonus, option acceleration

MADRIGAL PHARMACEUTICALS, INC.

Chief Commercial Officer Remy Sukhija leaves to pursue other opportunities, effective immediately.
Separation includes 12 months base salary and 40% target bonus paid over 12 months.
Stock options for 28,500 shares accelerated, becoming exercisable immediately.
Medical benefit coverage continued for 12 months post-departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Remy Sukhija

Chief Commercial Officer

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2023-09-25
Filed: September 25, 2023, 7:59 PM ET

Madrigal Pharmaceuticals, Inc. (the “Company”) reports that Remy Sukhija, who has served as the Company’s Chief Commercial Officer since April of 2020, is leaving the Company to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Remy Sukhija resigned as Chief Commercial Officer at MADRIGAL PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

Madrigal Pharmaceuticals, Inc. (the “Company”) reports that Remy Sukhija, who has served as the Company’s Chief Commercial Officer since April of 2020, is leaving the Company to pursue other opportunities.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-241315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.